Floatz Rating
B58/100
Confidence
Indicative
Sponsor
NuCana plc
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05340231CT.gov An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC) | — | Unknown | — | — | — |
NCT05084859CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04889820CT.gov Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer | — | Not Yet Recruiting | — | — | — |
NCT05116891CT.gov A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04895709CT.gov A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04553692CT.gov Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | — | Terminated | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04256707CT.gov Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | — | Completed | — | — | — |
NCT04165031CT.gov A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | — | Terminated | — | — | — |
Show 7 more trialsShow fewer
NCT03906565CT.gov Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer | — | Suspended | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT02039336CT.gov Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | — | Completed | — | — | — |
NCT00600496CT.gov A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | — | Completed | — | — | — |
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00003103CT.gov Chemotherapy in Treating Patients With Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | NuCana plc | P2 | B · 58 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →